OBJECTIVE： To explore the pharmacoeconomic effect of Ginkgo dipyidamolum， argatroban or sodium ozagerl combined with edaravone in the treatment of acute cerebral infarction （ACI）. METHODS： In retrospective study， 64 ACI patients were divided into group A （Ginkgo dipyidamolum+edaravone， 22 cases）， group B （argatroban+edaravone， 19 cases） and group C （sodium ozagerl+edaravone， 23 cases）. Therapeutic efficacies were observed after 7-14 days of treatment； therapy cost was calculated， and cost-minimization analysis was used to evaluate pharmacoeconomics. RESULTS： There was no statistical significance in total effective rate among 3 groups （P＞0.05）； the costs of group A，group B and group C were 8 746.36 yuan，10 770.64 yuan and 8 264.67 yuan. Results of sensitivity analysis were in line with those of cost-minimization analysis. CONCLUSIONS： Therapy plan of sodium ozagerl+edaravone is the economical regime in the treatment of ACI.